Published in the internationally respected Cochrane Library, the protocol ‘Smoking cessation interventions in adults with attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD)’ was developed by the South East Smokefree Alliance in collaboration with academics at the University of Bristol.
The work marks an important step towards building a stronger evidence base for helping adults stop smoking and stay smoke-free as part of a wider programme of research to address longstanding health inequalities.
Led by Dr Sarah Milne, Health Psychologist and South East Smokefree Alliance Lead with an honorary and visiting contract with the University of Bristol, and in collaboration with Dr Gemma Taylor, Senior Lecturer in Public Health at the University of Bristol, the planned review will examine what is known about the effectiveness of smoking cessation interventions for adults with ADHD, ASD, or both conditions, and identify where further research is needed.
It will assess behavioural, pharmacological and combined approaches to understand which interventions may be most effective, acceptable and accessible for different groups.
The publication comes as the South East Smokefree Alliance continues its wider programme of research, ‘Different brains, different approaches’, combining evidence review with new participant-led research designed to better understand the real-world experiences of people with ADHD and ASD who smoke.
Smoking remains one of the leading causes of preventable illness and death.
While smoking rates have declined significantly in the general population, research suggests adults with ADHD are substantially more likely to smoke and can experience greater nicotine dependence and more severe withdrawal symptoms when attempting to quit.
Adults with autism may face different challenges, including sensory preferences, communication differences, and the influence of routines and behavioural patterns on smoking behaviour.
Despite these differences, there is currently limited evidence to guide the adaptation of stop smoking support for neurodivergent adults.
Dr Sarah Milne, South East Smokefree Alliance Lead and lead author of the Cochrane protocol, said: “We know that people with ADHD and autism can face unique challenges when trying to stop smoking, but there is still far too little evidence about what support works best for them.
“When completed, the Cochrane review will help bring together the available evidence from around the world, identify gaps in knowledge and support the development of more inclusive and effective stop smoking services.
“We want to make sure that adults with ASD and ADHD in the South East and beyond are not left behind in tobacco control and smoking cessation efforts.”
Alongside the Cochrane review, the South East Smokefree Alliance is also leading a dedicated ADHD research project that seeks to understand smoking and quitting experiences directly from people with ADHD.
A major UK study found that adults with diagnosed ADHD had an estimated life expectancy 6.8 years lower for men and 8.6 years lower for women than people without a recorded diagnosis.
The researchers linked this gap not to ADHD itself, but to potentially preventable risks and unmet health needs.
Research has also found that people with autism spectrum disorder, without intellectual disability have an estimated life expectancy around six years lower than the general population.
Some studies suggest that smoking rates among people with ADHD may be as high as 40%, compared with 10.6% of adults across the UK, and the consequences for health could be profound.
Dr Milne’s study is exploring what unique barriers people with ADHD face when trying to quit smoking, and what types of support could make becoming smoke-free easier and more sustainable.
Central to the project is ensuring that people with lived experience help shape future stop smoking services and interventions.
By combining world-class evidence synthesis with real-world experiences, the programme aims to inform future policy, clinical practice and service design, helping to tackle health inequalities experienced by neurodivergent communities.
Dr Gemma Taylor, Senior Lecturer in Public Health at the University of Bristol, added: “Stop smoking support needs to reflect the people using it. By bringing together research evidence and the experiences of adults with ADHD and autism, we aim to understand how support can better meet their needs.
“This is an important step towards giving everyone the best possible chance of stopping smoking and improving their long-term health.”
Smoking is one of the biggest preventable causes of ill health and early death and likely to be a major driver of health inequalities for people with ASD and ADHD.
Dr Milne continued: “We cannot afford to overlook the need to understand why quitting smoking can be so much of a challenge for people with these neurodivergences and what would be the most effective way for people with ASD and ADHD to quit smoking.”
The Cochrane review is funded and supported by the South East Smokefree Alliance through the UK Government Local Stop Smoking Services and Support Grant.
People interested in learning more about the research programme or taking part in the ADHD study can visit the South East Smokefree Alliance website at www.quittogetherlivebetter.com/
Cochrane protocol
‘Smoking cessation interventions in adults with attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD)’ by Dr Sarah Milne, with contributions from Nicola Blake, Emma Jones, Casey Ingold, Beyza Cihan, Liz Bridge, Julian Lee Robinson and Gemma M.J. Taylor in the Cochrane Library [open access]